تقييم-مبني-الهرم.pdf
تقييم-مبني-الهرم.pdf

ISP-Haram-B.pdf
ISP-Haram-B.pdf

هيكل-المساهمين-27-3-2025.pdf
هيكل-المساهمين-27-3-2025.pdf

هيكل-المساهمين-31-12-2024.pdf
هيكل-المساهمين-31-12-2024-1-.pdf

مجلس-اداره-ابن-سينا-فارما30-9-23.pdf
مجلس-اداره-ابن-سينا-فارما30-9-23-1-.pdf

هيكل-المساهمين-لشركه-ابن-سينا-فارما.pdf
هيكل-المساهمين-لشركه-ابن-سينا-فارما-1-.pdf

الهيكل-التنظيمي-002-.pdf
الهيكل-التنظيمي.pdf

Court-Appeal.pdf
افصاح-حكم-محكمة-النقض.pdf

افصاح-المصالحة.pdf
افصاح-المصالحة.pdf

افصاح-القضية-19-2-2019.pdf
افصاح-القضية-19-2-2019.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The company sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 31/12/2018 according to Article 30 of the Listing Rules.

225432-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release from the company stating that it will begin distributing the products of the company "Alcon" during the first quarter of 2019.

225324-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company stating that the lawsuit was adjourned to be on 19/02/2019

224781-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release from the company stating that the lawsuit no. 1898 for the year 2016 was adjourned to be on 19/12/2018.

223941-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : The Board of Directors' decisions held on 08/11/2018

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company regarding the financial results for the period ended 30/09/2018

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 30/09/2018
Net Profit : 188,349,963
F/S Period: From 01/01/2017 To 30/09/2017
Net Comparative Profit : 143,079,626
Audit Status : Reviewed
Source : Ibnsina Pharma

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 30/09/2018
Net Profit : 188,349,963
F/S Period: From 01/01/2017 To 30/09/2017
Net Comparative Profit : 143,079,626
Audit Status : Reviewed
Source : Ibnsina Pharma

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company regarding the BOD's meeting to be held on 08/11/2018

223081-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
AGM minutes (after certification)
Assembly Date : 02/04/2018

222923-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The company sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 30/09/2018, according to Article 30 of the Listing Rules.

222414-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
EGX decided to resume trading on the company effective 01/10/2018 trading session at 2:20 PM.

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The company sent a release regarding the news published on one of the websites titled "The arrest of the Managing Director of Ibn Sina Pharma due to the issue of drug monopoly".

221763-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
EGX decided to suspend trading on the company effective 01/10/2018 till the company responds to EGX inquiries concerning what was published on one of the websites.

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company stating that the lawsuit was adjourned to be on 19/11/2018

221236-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release concerning the semi-annual disclosure form concerning the proceeds of the capital increase.

220976-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The Board of Directors' decisions held on 09/08/2018.

Release in Arabic (1,745 KB)
219979-2.pdf
219979-3.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 30/06/2018
Net Profit : 75,183,179
F/S Period: From 01/01/2017 To 30/06/2017
Net Comparative Profit : 53,662,578
Audit Status : Reviewed
Source : Ibnsina Pharma

219980-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 30/06/2018
Net Profit : 75,183,179
F/S Period: From 01/01/2017 To 30/06/2017
Net Comparative Profit : 53,662,578
Audit Status : Reviewed
Source : Ibnsina Pharma

219980-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release was sent regarding the BOD's meeting to be held on 09/08/2018

219547-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Reference to what was published on 20/06/2018, the company sent a release from stating that the lawsuit was adjourned to 18/09/2018.

219202-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The company sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 30/06/2018 according to Article 30 of the Listing Rules.

218944-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company denying the existence of any contractual relations or association with Abraaj Capital Group

218662-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company stating that the lawsuit was adjourned to 16/07/2018

218149-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The Listing Committee held on 06/06/2018 decided to address the company to abide by the provision of Article 31 of the Listing Rules and 45 of the Executive Regulations.

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release was sent regarding a lawsuit against the company, with a session scheduled for Monday 19/06/2018

217180-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release was sent concerning the financial results for the period ended 31/03/2018

216841-2.pdf
216841-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : The Board of Directors' decisions held on 13/05/2018

216748-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 31/03/2018
Net Profit : 27,954,173
F/S Period: From 01/01/2017 To 31/03/2017
Net Comparative Profit : 19,105,202
Audit Status : Reviewed
Source : Ibnsina Pharma

216749.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2018 To 31/03/2018
Net Profit : 27,954,173
F/S Period: From 01/01/2017 To 31/03/2017
Net Comparative Profit : 19,105,202
Audit Status : Reviewed
Source : Ibnsina Pharma

216749-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company regarding the BOD's meeting to be held on 13/05/2018

216513-1.pdf

ISPH.CA
 
The listing committee held on 17-04-2018 has approved to list the company's capital increase from EGP 168 Million  to EGP  180.5 Million   , such capital increase amounted to EGP 12.5 Million   distributed over 50 Million shares at par value of EGP 0.25 per share  paid in cash .
These new shares will be added to Egx database starting 24/04/2018 trading session.
The company is committed to lock-up all shares of this capital increase that amounted to 50,000,000 shares to fulfill terms of its share lock-up as set in the placement prospectus of the company's shares , in accordance with the item no. (7) of the article no. (7) of the listing rules, provided that the lock-up period shall be completed for "eighteen months from the date of trading its shares in the Egyptian Exchange" according to the letter received from MCDR on 16\04\2018.

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The company sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 31/03/2018 according to Article 30 of the Listing Rules.

215552-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release from the company concerning the Board of Directors & the Executive Managers.

215102-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
AGM Decisions
Assembly Date : 02/04/2018

214910-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :The Audit Committee’s minutes for the period ended 31/12/2017

214456-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company concerning the completion of the commercial register and the release of the proceeds of the capital increase of 290 million pounds

214204-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Press release regarding the signing of two contracts with Novo Nordisk Company.

214204-2.pdf
214204-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Currency : EGP
F/S Period : From 01/01/2017 To 31/12/2017
Net Profit : 170,137,041
F/S Period: From 01/01/2016 To 31/12/2016
Net Comparative Profit : 101,747,851
Audit Status : Audited
Source : Ibnsina Pharma

213851-2.pdf
213851-3.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release from the company concerning the call for the AGM which is scheduled to be held on 02/04/2018

213854-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :The Board of Directors' decisions held on08/03/2018

213853-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The Board of Directors' meeting minutes held on 04/03/2018 concerning the unaudited financial results for the period ended 31/12/2017.

The Minutes (2,686 KB)
213488-3.pdf
213488-2.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Referring to the announcement published on the trading screens regarding the latest developments of case no. 2952 for the year 2015, the economic census and number 1898 for the year 2016 economic misdemeanors and clarification from the company note that the company appealed the ruling before the competent authorities and was set on Saturday, 19/05/2018 in front of Second Circuit Resume.

213413-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release from the company concerning the latest developments of the case No. 2952 for the year 2015 inventory commercial restricted number 1898 to 2016 commercial misdemeanors.

213346-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The Board of Directors' meeting minutes held on 28/02/2018.

213323-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
Release from the company regarding its sales and market share.

211994-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
The Board of Directors' meeting minutes held on 17/01/2018.

211938-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :
EGM minutes (after certification)
Assembly Date : 01/11/2017

211944-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content :The company sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 31/12/2017 according to Article 30 of the Listing Rules.

211802-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : ISPH.CA
Content : Release was sent regarding the company's stabilization fund.

211438-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :Release was sent concerning the investor relations officer

211307-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content : Release was sent concerning the Board of Directors & the Executive Managers

211309-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content : EGM minutes (after certification)
Assembly Date : 24/10/2017

211060-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Disclosures from the company.

News' Attachment I (604 KB)
210775-2.pdf
210775-3.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Disclosures from the company.

News' Attachment I (574 KB)
News' Attachment II (560 KB)
News' Attachment III (626 KB)
210774-4.pdf
210774-5.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Release regarding the final price of the company's share.

210673-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Additional release from the company.

210412-1.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Disclosures from the company.

News' Attachment I (626 KB)
News' Attachment II (1,236 KB)
News' Attachment III (3,232 KB)
210403-4.pdf
210403-5.pdf

Company Name : Ibnsina Pharma
ISIN Code : EGS512O1C012
Reuters Code : IBNP.CA
Content :
Release regarding FRA's approval on the prospectus of the initial public offering of the company.
News-Attachment-I.pdf
News-Attachment-II.pdf

The Listing Committee held on 08/11/2017 has approved to list the shares of Ibnsina Pharma (initially listing)
The company’s issued capital is EGP 168 Million, distributed over 672 million shares at a par value of LE 0.25 per share, to be listed in the Egyptian Securities Board- Stocks.
According to the Listing Rules set by EFSA board of directors’ resolution